Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study.

Autor: Nothegger B; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Reider N; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Covaciu CE; Department of Dermatology Venereology and Allergology, Central Teaching Hospital, Bolzano/Bozen, Italy., Cova V; Department of Applied Genomics and Molecular Biology, Laimburg Research Centre, Ora, Italy., Ahammer L; Institute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria., Eidelpes R; Institute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria., Unterhauser J; Institute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria., Platzgummer S; Clinical Chemistry and Microbiology Laboratory, Tappeiner Hospital, Meran, Italy., Raffeiner E; Clinical Chemistry and Microbiology Laboratory, Tappeiner Hospital, Meran, Italy., Tollinger M; Institute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria., Letschka T; Department of Applied Genomics and Molecular Biology, Laimburg Research Centre, Ora, Italy., Eisendle K; Department of Dermatology Venereology and Allergology, Central Teaching Hospital, Bolzano/Bozen, Italy.; IMREST Interdisciplinary Medical Research Center South Tyrol, Claudiana College of Health-Care Professions, Bolzano/Bozen, Italy.
Jazyk: angličtina
Zdroj: Immunity, inflammation and disease [Immun Inflamm Dis] 2021 Jun; Vol. 9 (2), pp. 503-511. Date of Electronic Publication: 2021 Feb 23.
DOI: 10.1002/iid3.410
Abstrakt: Background: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen-related food allergy (prFA), especially to apples, due to a clinically relevant cross-reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen-specific immunotherapy with fresh apples (AITA) could be a promising natural treatment of both BPA and prFA.
Objective: To assess the clinical efficacy of immunotherapy by daily apple consumption for patients with BPA and prFA.
Methods: A daily defined increasing amount of selected cultivars (Red Moon®, Pink Lady®, Topaz, Golden Delicious) was continuously consumed by 16 patients (12 female; median age; 50; range, 23-68 years), leading to increased intake of allergen over a period of at least 8 months. Specific IgE and IgG 4 to Bet v 1 and Mal d 1, conjunctival and oral provocation tests, skin reactivity, and the average daily rhinoconjunctivitis combined symptom and medication score (CSMS) were measured during the peak birch pollen season.
Results: After 8 months of therapy, patients showed increased tolerance to apples (p < .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p < .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p < .001), as did conjunctival reactivity to birch pollen extract by 27% (p < .01), while specific IgG 4 to Mal d 1 and Bet v 1 increased (p < .01).
(© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje